Deciphering the uranium target proteins in human dopaminergic SH-SY5Y cells

Mutant variants of mini-intein PRP8 from Penicillium chrysogenum (Int4b) with improved control of C-terminal processing were characterized. The presented variants can serve as a basis for self-removed polypeptide tags capable of carrying an affine label and allowing to optimize the process of obtaining target proteins and peptides in E. coli cells. They allow to synthesize target molecules in the composition of soluble and insoluble hybrid proteins (fusions), provide their afnne purification, autocatalytic processing and obtaining mature target products. The presented variants have a number of features in comparison with the known prototypes. In particular the mutant mini-intein Int4bPRO, containing the L93P mutation, has temperature-dependent properties. At cultivation temperature below 30 °C it allows the production of target molecules as part of soluble fusions, but after increasing of cultivation temperature to 37 °C it directs the most of synthesized fusions into insoluble intracellular aggregates. The transition of Int4bPRO into insoluble form is accompanied by complete inactivation of C-terminal processing. Further application of standard protein denaturation-renaturation procedures enable efficiently reactivate Int4bPRO and to carry out processing of its fusions in vitro. Two other variants, Int4b56 and Int4b36, containing a point mutation T62N or combination of mutations D144N and L146T respectively, have a reduced rate of C-terminal processing. Their use in E. coli cells allows to optimize the biosynthesis of biologically active target proteins and peptides in the composition of soluble fusions, suitable for afnne purification and subsequent intein-dependent processing without the use of protein denaturation-renaturation procedures. intein, fusion, processing, processing rate, gelonin The work was supported within the framework of the State Assignment no. 595-00003-19 PR.

Download Full-text

Promiscuous Binding Nature of Sh3 Domains to their Target Proteins

Protein and Peptide Letters ◽

10.2174/0929866023408760 ◽

2002 ◽

Vol 9 (3) ◽

pp. 185-193 ◽

Cited By ~ 27

Author(s):

Vishal Agrawal ◽

K.V. Kishan

Keyword(s):

Sh3 Domains ◽

Target Proteins

Download Full-text

Molecular pathways of Interferon–Stimulated Gene 15: Implications in cancer

Current Protein and Peptide Science ◽

10.2174/1389203721999201208200747 ◽

2020 ◽

Vol 21 ◽

Author(s):

Angeles C. Tecalco–Cruz

Keyword(s):

Posttranslational Modification ◽

Human Interferon ◽

Molecular Pathways ◽

Biological Processes ◽

Small Protein ◽

Target Proteins ◽

Central Elements ◽

Cancer Types ◽

Interferon Stimulated Gene 15

Abstract:: Human interferon–stimulated gene 15 (ISG15) is a 15–kDa ubiquitin–like protein that can be detected as either free ISG15 or covalently associated with its target proteins through a process termed ISGylation. Interestingly, extracellular free ISG15 has been proposed as a cytokine–like protein, whereas ISGylation is a posttranslational modification. ISG15 is a small protein with implications in some biological processes and pathologies that include cancer. This review highlights the findings of both free ISG15 and protein ISGylation involved in several molecular pathways, emerging as central elements in some cancer types.

Download Full-text

Anesthetics Mechanisms: A Review of Putative Target Proteins at the Cellular and Molecular Level

Current Drug Targets ◽

10.2174/1389450119666180502112029 ◽

2018 ◽

Vol 19 (11) ◽

pp. 1333-1343 ◽

Cited By ~ 1

Author(s):

Danuh Kim ◽

Hyun Joo Kim ◽

Seunghyun Ahn

Keyword(s):

Molecular Level ◽

Target Proteins ◽

Putative Target

Download Full-text

Drug repurposing using similarity-based target prediction, docking studies and scaffold hopping of lefamulin

Letters in Drug Design & Discovery ◽

10.2174/1570180817999201201113712 ◽

2020 ◽

Vol 17 ◽

Author(s):

Shikha Sharma ◽

Shweta Sharma ◽

Vaishali Pathak ◽

Parwinder Kaur ◽

Rajesh Kumar Singh

Keyword(s):

In Silico ◽

Target Prediction ◽

Drug Repurposing ◽

Docking Studies ◽

Target Protein ◽

Future Perspective ◽

Antibacterial Drug ◽

Scaffold Hopping ◽

Target Proteins ◽

Renin Inhibitors

Aim: To investigate and validate the potential target proteins for drug repurposing of newly FDA approved antibacterial drug. Background: Drug repurposing is the process of assigning indications for drugs other than the one(s) that they were initially developed for. Discovery of entirely new indications from already approved drugs is highly lucrative as it minimizes the pipeline of the drug development process by reducing time and cost. In silico driven technologies made it possible to analyze molecules for different target proteins which are not yet explored. Objective: To analyze possible targets proteins for drug repurposing of lefamulin and their validation. Also, in silico prediction of novel scaffolds from lefamulin has been performed for assisting medicinal chemists in future drug design. Methods: A similarity-based prediction tool was employed for predicting target protein and further investigated using docking studies on PDB ID: 2V16. Besides, various in silico tools were employed for prediction of novel scaffolds from lefamulin using scaffold hopping technique followed by evaluation with various in silico parameters viz., ADME, synthetic accessibility and PAINS. Results: Based on the similarity and target prediction studies, renin is found as the most probable target protein for lefamulin. Further, validation studies using docking of lefamulin revealed the significant interactions of lefamulin with the binding pocket of the target protein. Also, three novel scaffolds were predicted using scaffold hopping technique and found to be in the limit to reduce the chances of drug failure in the physiological system during the last stage approval process. Conclusion: To encapsulate the future perspective, lefamulin may assist in the development of the renin inhibitors and, also three possible novel scaffolds with good pharmacokinetic profile can be developed into both as renin inhibitors and for bacterial infections.

Download Full-text

None-Loss Target Release of Biomimetic CaCO3 Nanocomposites for Screening Bioactive Components and Target Proteins

ACS Applied Bio Materials ◽

10.1021/acsabm.0c01197 ◽

2020 ◽

Author(s):

Yingying Tang ◽

Wenhui Qian ◽

Bei Zhang ◽

Wenya Liu ◽

Xuetong Sun ◽

...

Keyword(s):

Bioactive Components ◽

Target Proteins

Download Full-text